(Total Views: 474)
Posted On: 10/09/2019 2:47:13 PM
Post# of 154754
This is how I think it will work:
1) CYDY pays for manufacturing the drug, which yields "cost"
2) CYDY transfers the drug to Partner A (PA), PA pays CYDY cost (or COGS, which is more) + 10%. Now the drug is sitting on PA's balance sheet in inventory waiting to be sold.
3) PA sells the drug
4) PA pays CYDY 50% of the sales price
+++++
I am not sure about the milestone payments. For one, I am not sure if the $90M is inclusive or exclusive of the $50M launch money. I would assume it is inclusive -- i.e. $90M total and not $140M -- but that is just a guess. And we obviously don't know what the milestones are. Hopefully, part 2 of the BLA submission is a big one given that that is our closest.
1) CYDY pays for manufacturing the drug, which yields "cost"
2) CYDY transfers the drug to Partner A (PA), PA pays CYDY cost (or COGS, which is more) + 10%. Now the drug is sitting on PA's balance sheet in inventory waiting to be sold.
3) PA sells the drug
4) PA pays CYDY 50% of the sales price
+++++
I am not sure about the milestone payments. For one, I am not sure if the $90M is inclusive or exclusive of the $50M launch money. I would assume it is inclusive -- i.e. $90M total and not $140M -- but that is just a guess. And we obviously don't know what the milestones are. Hopefully, part 2 of the BLA submission is a big one given that that is our closest.
(0)
(0)
